ArticleHealth science reports2026
Efficacy and Safety of Messenger RNA Vaccines.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The rapid development of mRNA vaccines has revolutionized infectious disease prevention and cancer immunotherapy. While their efficacy is well established, concerns about safety and immunopathological risks persist. This study aims to evaluate the immunogenicity, safety profiles, and design considerations of mRNA vaccines to optimize their protective benefits while minimizing adverse effects. Methods: A comprehensive literature review was conducted, including clinical trials, preclinical studies, and pharmacovigilance reports from 2015 to 2025, focusing on vaccine mechanisms, immune responses, and safety outcomes. Results: mRNA vaccines utilize lipid nanoparticles (LNPs) for delivery, effectively inducing robust humoral and cellular immunity. Clinical data reveal high protection levels, but rare adverse effects such as vascular inflammation, myocarditis, and autoimmune phenomena have been reported. Achieving an optimal balance between strong immune activation and tolerability remains a key challenge. Ongoing research explores personalized vaccine strategies, improved delivery systems, and advanced safety surveillance to address individual variability and long-term safety. Conclusion: mRNA vaccine technology offers unparalleled flexibility and potency, with a promising safety profile when carefully optimized. Continued technological refinement, personalized approaches, and vigilant safety monitoring are essential to fully harness its potential. Responsible innovation will be pivotal in advancing mRNA platforms to meet global health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.